Presentation is loading. Please wait.

Presentation is loading. Please wait.

Steve Elias MD FACS FACPh Director, Division of Vascular Surgery Vein Programs Columbia University and Medical Center, NY Assistant Professor of Surgery.

Similar presentations


Presentation on theme: "Steve Elias MD FACS FACPh Director, Division of Vascular Surgery Vein Programs Columbia University and Medical Center, NY Assistant Professor of Surgery."— Presentation transcript:

1 Steve Elias MD FACS FACPh Director, Division of Vascular Surgery Vein Programs Columbia University and Medical Center, NY Assistant Professor of Surgery Columbia University

2  Vascular Insights LLC – Advisory Board  Covidien Inc. – Advisory Board

3

4  Combination – endovenous mechanical and chemical  Mechanical – wire > rotates > intimal damage  Chemical – liquid > penetrates > scar  End result – venous occlusion

5

6

7

8  Percutaneous ultrasound guided  4 fr. micropunture sheath  18 gauge IV access  No further wires or larger sheath exchange

9

10

11  Pullback 1.o – 1.5 mm. per second  Inject during pullback  Sodium tetradecyl sulfate 1.5% liquid (or equivalent sclerosant)  Volume dependent on size/length

12

13

14

15

16

17  30 limbs  GSV only  C2 – 24 C3 – 2 C4 – 4  Avg. 55 years  Treat GSV only (no treatment VV or IPV)  1 yr. follow up to complete trial  No tumescence or sedation *Elias S, Raines JK. Mechanochemical tumescentless endovenous ablation: final results of the initial clinical trial. Phlebology;27:67-72.

18  GSV size – 8.1 mm.  GSV length treated – 36 cm.  GSV treatment time – 5 min.  Overall treatment time - 14 min

19  All closed except 1 st patient – btw 3-6mos  6 month – 29/30 (96%)  12 month – 29/30 (96%)  24 month – 27/28 (96%) ( 1 died, 1 no US yet) *Elias S, Raines JK. Mechanochemical tumescentless endovenous ablation: final results of the initial clinical trial. Phlebology;27:67-72.

20  Subcutaneous ecchymoses – 3 pts.  Side branch tear?  No DVT  No nerve injury  No skin injury

21  224 GSV’s  C2 (13%)C3 (67%) C4 (20%)  GSV diameter 7 mm  GSV length 41 cm  treatment time 16 min Ramon RJP, van Eekeren MD et al. Endovenous mechanochemical ablation of great saphenous vein incompetence using the ClariVein device: a safety study. J Endovasc Ther 2011; 18:

22  6 weeks – 182/185 closed 98%  6 months – 40/42 closed 95%  No nerve/skin/DVT

23  6,000 cases worldwide (GSV/SSV)  > 90% occlusion rate – various intervals  Chaloner – 92% at 1 yr.  QoL – improves as any successful EVA  DVT - < 1%  No nerve/skin injury  No tumescence – longest part of short procedure

24  Rotate 1 st (spasm/vortex) then inject slow  Catheter ON = Catheter MOVING  Two handed technique – 1 pulls – 1 injects  Tendency: Pull too fast, inject too slow

25  Volume originally 12 cc (1.5%STD) for all  Volume now based on diameter/length  Volume tends to be less  Table available  GSV – 6-10 cc SSV – 2-4 cc PPV – 1cc

26  Stronger is better  STD 1.5% - 2% 93-96% 1% < 90% (Chaloner UK)  PLD – 2 – 3 % (volume based on weight)  Lower volume, maximum concentration

27  Slower contraction and scarring  No flow but appears sponge like (color flow)  Can take up to 1 year for contraction  If some flow – reimage 3 months

28

29  No thermal injury – nerves, skin  SSV, BK GSV, PPV  Ulcers – retrograde  Eliminates tumescence – patient and MD

30  It works, It is safe – 96% at 2 years  Learning curve - 5 – 8 cases  No tumescence – the future, only one now  Glue, PEM, TAHOE (RF)  Another good option for ablation (95% pts.)

31  Respect the elders,  Embrace the new,  Encourage the improbable and impractical  Without bias


Download ppt "Steve Elias MD FACS FACPh Director, Division of Vascular Surgery Vein Programs Columbia University and Medical Center, NY Assistant Professor of Surgery."

Similar presentations


Ads by Google